140 related articles for article (PubMed ID: 16144797)
21. Significance of antiprothrombin antibodies in patients with systemic lupus erythematosus: clinical evaluation of the antiprothrombin assay and the antiphosphatidylserine/prothrombin assay, and comparison with other antiphospholipid antibody assays.
Tsutsumi A; Hayashi T; Chino Y; Mamura M; Goto D; Matsumoto I; Ito S; Sumida T
Mod Rheumatol; 2006; 16(3):158-64. PubMed ID: 16767554
[TBL] [Abstract][Full Text] [Related]
22. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
Mustonen P; Lehtonen KV; Javela K; Puurunen M
Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
[TBL] [Abstract][Full Text] [Related]
23. Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus.
Marchetti T; Ribi C; Perneger T; Trendelenburg M; Huynh-Do U; de Moerloose P; Chizzolini C
Rheumatology (Oxford); 2018 Aug; 57(8):1350-1357. PubMed ID: 29672737
[TBL] [Abstract][Full Text] [Related]
24. A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients.
Nojima J; Motoki Y; Aoki N; Tsuneoka H; Ichihara K
Thromb Res; 2014 Jun; 133(6):1135-40. PubMed ID: 24721837
[TBL] [Abstract][Full Text] [Related]
25. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
26. Anti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.
Inanç M; Donohoe S; Ravirajan CT; Radway-Bright EL; Mackie I; Machin S; Isenberg DA
Br J Rheumatol; 1998 Oct; 37(10):1089-94. PubMed ID: 9825748
[TBL] [Abstract][Full Text] [Related]
27. High frequency of abnormal levels of IgA anti-beta2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome.
Fanopoulos D; Teodorescu MR; Varga J; Teodorescu M
J Rheumatol; 1998 Apr; 25(4):675-80. PubMed ID: 9558168
[TBL] [Abstract][Full Text] [Related]
28. Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism.
Nojima J; Kuratsune H; Suehisa E; Iwatani Y; Kanakura Y
Clin Chem; 2005 Mar; 51(3):545-52. PubMed ID: 15637132
[TBL] [Abstract][Full Text] [Related]
29. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.
Danowski A; Kickler TS; Petri M
J Rheumatol; 2006 Sep; 33(9):1775-9. PubMed ID: 16960938
[TBL] [Abstract][Full Text] [Related]
30. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.
Horbach DA; van Oort E; Donders RC; Derksen RH; de Groot PG
Thromb Haemost; 1996 Dec; 76(6):916-24. PubMed ID: 8972011
[TBL] [Abstract][Full Text] [Related]
31. Non-criteria manifestations in the presence of antiphospholipid antibodies in a paediatric cohort.
Morán-Álvarez P; Andreu-Suárez Á; Caballero-Mota L; Gassiot-Riu S; Berrueco-Moreno R; Calzada-Hernández J; Antón-López J; Vázquez-Díaz M; Boteanu A
Rheumatology (Oxford); 2022 Nov; 61(11):4465-4471. PubMed ID: 35137009
[TBL] [Abstract][Full Text] [Related]
32. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
[TBL] [Abstract][Full Text] [Related]
33. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
[TBL] [Abstract][Full Text] [Related]
34. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodies are at risk for clinical manifestations related to the antiphospholipid syndrome.
Gattorno M; Buoncompagni A; Molinari AC; Barbano GC; Morreale G; Stalla F; Picco P; Mori PG; Pistoia V
Br J Rheumatol; 1995 Sep; 34(9):873-81. PubMed ID: 7582730
[TBL] [Abstract][Full Text] [Related]
35. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus.
Szodoray P; Tarr T; Tumpek J; Kappelmayer J; Lakos G; Poor G; Szegedi G; Kiss E
Autoimmunity; 2009 Sep; 42(6):497-506. PubMed ID: 19626489
[TBL] [Abstract][Full Text] [Related]
36. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus.
Nojima J; Iwatani Y; Suehisa E; Kuratsune H; Kanakura Y
Haematologica; 2006 May; 91(5):699-702. PubMed ID: 16627257
[TBL] [Abstract][Full Text] [Related]
37. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome.
von Scheven E; Glidden DV; Elder ME
Arthritis Rheum; 2002 Aug; 47(4):414-20. PubMed ID: 12209489
[TBL] [Abstract][Full Text] [Related]
38. Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients.
Gómez-Pacheco L; Villa AR; Drenkard C; Cabiedes J; Cabral AR; Alarcón-Segovia D
Am J Med; 1999 Apr; 106(4):417-23. PubMed ID: 10225244
[TBL] [Abstract][Full Text] [Related]
39. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients.
Tarr T; Lakos G; Bhattoa HP; Shoenfeld Y; Szegedi G; Kiss E
Lupus; 2007; 16(1):39-45. PubMed ID: 17283584
[TBL] [Abstract][Full Text] [Related]
40. Antibodies to anionic phospholipids and anti-beta2-GPI: association with thrombosis and thrombocytopenia in systemic lupus erythematosus.
Amoroso A; Mitterhofer AP; Del Porto F; Garzia P; Ferri GM; Galluzzo S; Vadacca M; Caccavo D; Afeltra A
Hum Immunol; 2003 Feb; 64(2):265-73. PubMed ID: 12559629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
